Xilio Therapeutics, Inc. – NASDAQ:XLO
Xilio Therapeutics stock price today
$0.684
-0.28
-29.7%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
Xilio Therapeutics stock price monthly change
-4.71%
month
Xilio Therapeutics stock price quarterly change
-4.71%
quarter
Xilio Therapeutics stock price yearly change
+76.86%
year
Xilio Therapeutics key metrics
Market Cap | 50.99M |
Enterprise value | N/A |
P/E | -1.01 |
EV/Sales | N/A |
EV/EBITDA | 0.06 |
Price/Sales | N/A |
Price/Book | 0.89 |
PEG ratio | -0.01 |
EPS | -2.57 |
Revenue | N/A |
EBITDA | -70.30M |
Income | -70.96M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeXilio Therapeutics stock price history
Xilio Therapeutics stock forecast
Xilio Therapeutics financial statements
| Jun 2023 | 0 | -19.35M | |
|---|---|---|---|
| Sep 2023 | 0 | -16.74M | |
| Dec 2023 | 2.90M | -17.65M | -608.37% |
| Mar 2024 | 0 | -17.20M |
| Mar 2024 | 0 | -17.20M | |
|---|---|---|---|
| Sep 2025 | 0 | -4.13M | |
| Oct 2025 | 0 | -2.79M | |
| Dec 2025 | 75M | 8.09M | 10.79% |
Analysts Price target
Financials & Ratios estimates
| 2024-05-14 | -0.3 | -0.59 |
|---|
| Jun 2023 | 92359000 | 24.98M | 27.05% |
|---|---|---|---|
| Sep 2023 | 77842000 | 25.34M | 32.56% |
| Dec 2023 | 60926000 | 24.09M | 39.55% |
| Mar 2024 | 82609000 | 56.84M | 68.81% |
| Jun 2023 | -16.57M | -316K | -992 |
|---|---|---|---|
| Sep 2023 | -13.36M | 0 | -2.23K |
| Dec 2023 | -13.42M | 0 | -1.63M |
| Mar 2024 | -10.50M | 0 | 954K |
Xilio Therapeutics alternative data
| Aug 2023 | 89 |
|---|---|
| Sep 2023 | 84 |
| Oct 2023 | 84 |
| Nov 2023 | 84 |
| Dec 2023 | 81 |
| Jan 2024 | 81 |
| Feb 2024 | 81 |
| Mar 2024 | 81 |
| Apr 2024 | 81 |
| May 2024 | 73 |
| Jun 2024 | 73 |
| Jul 2024 | 56 |
Xilio Therapeutics other data
15.88%
-42.24%
of XLO is owned by hedge funds
14
-14
4.35M
-11.57M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 4235 |
| Feb 2024 | 0 | 1000 |
| Apr 2024 | 4367700 | 0 |
| Dec 2024 | 7852794 | 0 |
-
What's the price of Xilio Therapeutics stock today?
One share of Xilio Therapeutics stock can currently be purchased for approximately $0.68.
-
When is Xilio Therapeutics's next earnings date?
Unfortunately, Xilio Therapeutics's (XLO) next earnings date is currently unknown.
-
Does Xilio Therapeutics pay dividends?
No, Xilio Therapeutics does not pay dividends.
-
How much money does Xilio Therapeutics make?
Xilio Therapeutics has a market capitalization of 50.99M. Xilio Therapeutics made a loss 76.4M US dollars in net income (profit) last year or -$0.59 on an earnings per share basis.
-
What is Xilio Therapeutics's stock symbol?
Xilio Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "XLO".
-
What is Xilio Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Xilio Therapeutics?
Shares of Xilio Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Xilio Therapeutics have?
As Jul 2024, Xilio Therapeutics employs 56 workers, which is 23% less then previous month and 31% less then previous quarter.
-
When Xilio Therapeutics went public?
Xilio Therapeutics, Inc. is publicly traded company for more then 3 years since IPO on 22 Oct 2021.
-
What is Xilio Therapeutics's official website?
The official website for Xilio Therapeutics is xiliotx.com.
-
Where are Xilio Therapeutics's headquarters?
Xilio Therapeutics is headquartered at 828 Winter Street, Waltham, MA.
-
How can i contact Xilio Therapeutics?
Xilio Therapeutics's mailing address is 828 Winter Street, Waltham, MA and company can be reached via phone at +61 74304680.
Xilio Therapeutics company profile:
Xilio Therapeutics, Inc.
xiliotx.comExchange:
NASDAQ
Full time employees:
73
Industry:
Biotechnology
Sector:
Healthcare
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
828 Winter Street
Waltham, MA 02451
Waltham, MA 02451
CIK: 0001840233
ISIN: US98422T1007
CUSIP: 98422T100
